This is believed to be the first randomized clinical trial focused on treating AAAs with an angiotensin receptor blocker.
The role of ACE inhibitors and ARBs in the treatment of COVID-19 has been a key topic for researchers since the pandemic began. This latest research represents a significant update for clinicians.
The study's authors tracked 450 patients with uncontrolled high blood pressure.
Researchers tracked more than 3,300 older patients for three years, performing clinical assessments every six months.
The BRACE CORONA trial focused on the safety of taking angiotensin-converting enzyme inhibitors and angiotensin receptor blockers when hospitalized with COVID-19.
The study's authors explored data from more than 28,000 patients.
The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is associated with a lower risk of colorectal cancer.
A new analysis explored if age, numerous comorbidities, the use of CVD medication and Charleston Comorbidity Index scores can be used to predict mortality among confirmed COVID-19 patients.
Hypertension is associated with a much greater risk of dying from COVID-19, according to new research published in European Heart Journal. The study’s authors noted that outcomes improved if patients took antihypertensive medications as recommended.
Ambient air pollution directly leads to poorer health outcomes, and even short-term exposure to fine particulate matter can increase a person’s risk of adverse cardiovascular events.
Numerous healthcare organizations have joined forces to launch a new ad campaign focused on helping black women learn more about monitoring and managing their blood pressure.
The guidelines were specifically designed so that they could apply to patients from any country or socioeconomic group.